Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Pembrolizumab plus chemoradiotherapy shows early promise in NSCLC
Key clinical point: Combination pembrolizumab and chemoradiotherapy appears tolerable and active in patients with locally advanced non–small cell lung cancer.
Major finding: There was one dose-limiting toxicity – grade 5 pneumonitis in a safety expansion cohort – and 89% of evaluable patients achieved a partial or complete response.
Study details: A phase 1 trial of 21 patients with stage III NSCLC.
Disclosures: The study was funded by Merck. The authors disclosed relationships with Merck and other companies.
Citation:
Jabbour SK et al. JAMA Oncol. 2020 Feb 20. doi: 10.1001/jamaoncol.2019.6731.